… Phase I/II trials, for treatment of metastatic pancreatic cancer. … Erlotinib, an EGFR tyrosine
kinase inhibitor, represents the … IGF-1 receptor, was demonstrated to amplify the gemcitabine …

… on vismodegib or cixutumumab until disease progression or … , gemcitabine, cyclophosphamide,
panitumumab, erlotinib or … metastatic pancreatic adenocarcinoma were randomized 1:1:…

… Phase II trial of cetuximab, gemcitabine, and oxaliplatin … and erlotinib: preclinical evaluation
and results of the phase II … Phase I/II trial and pharmacokinetic study of cixutumumab in …

… The insulin-like growth factor receptor 1 (IGF-1R) is another … -IGF-1R antibodies including
cixutumumab show to augment … signals in combination with erlotinib in phase II trials of lung …

… of IGF-1 with high affinity for insulin-like growth factor type 1 receptor. The study aim was to
… 47 phase III ganiumumab plus gemcitabine pancreatic adenocarcinoma trial, 48 and phase …

… of metastatic pancreatic cancer and metastatic colon cancer, … Other IGF1R monoclonal
antibodies, including cixutumumab, … cancer, and linsitinib maintenance with erlotinib, a TKI of the …

… insulin-like growth factor receptor 1 association with oncology. … Phase II trial tested
cixutumumab (IMC-A12) alone or in … Phase 1 clinical trial of OSI-906 and erlotinib exhibited …

… insulin-like growth factor (IGF)-axis was implicated in cancer … antibody (MAb), Cixutumumab,
induced Akt and mammalian … signaling regulates type IV collagen production in metastatic …

… Nowadays, the only approved first-line drug for metastatic … effect of Erlotinib and NVP-AEW541
on the tumor growth of SW13 … Therapeutic effect with erlotinib and gemcitabine has been …

… Insulin-like growth factor (IGF) signaling promotes cell … In this study, cixutumumab decreased
IGF-IR phosphorylation in … patients with locally advanced or metastatic thyroid cancer [77], …